Company Profile
NeoClone
Antibodies
Cancer
Diagnostics
1202 Ann St.
Madison, WI 53713
USA
www.neoclone.com
|
Incorporated in 1999
10 Employees
|
Privately Held
|
|
This Year's Highlights
- Patent applications filed for novel fully human antibody platform and in vitro monoclonal antibody development. Full filing in December of '07
- NeoClone has entered into its 15th institutional partnering agreement. These agreements allow researchers access to discounted mAb development services in exchange for commercialization rights.
- We are now servicing 5 of the top 20 Pharma companies. In addition, we were awarded a $750K contract for mAb development from the National Cancer Institute in May of '07. Further, we have received 2 SBIR Phase I grants for $250K in August of '07.
|
Anticipated Highlights
- Cash flow positive in Q3 of '07
- Proof of concept that mAbs we develop have therapeutic potential in Q1 '08.
- Demonstrate that the current business model can be long-term profitable in '08.
|
|
Corporate Mission
NeoClone excells in the development of monoclonal antibodies. Using our propritery process, we have been servicing the market since 1999. Further, we are advancing our technology to develop fully human mAbs.
|
